Updated Thyroid Cancer Guidelines: Personalized Approaches for Optimized Care
2026 Division of Endocrinology Grand Rounds
-
This Grand Rounds will examine the American Thyroid Association’s 2025 guidelines and their implications for the care of patients with thyroid cancer. Matthew Ringel, an expert in endocrine-related cancers and a visiting professor from The Ohio State University College of Medicine, will discuss evolving approaches to early-stage disease, the role of molecular testing in diagnosis and treatment planning, and management strategies for radioiodine-resistant disease. The session will highlight practical considerations for applying guideline-based care across diverse clinical presentations.
Speaker: Matthew Ringel, MD, is the founding chair of the Department of Molecular Medicine and Therapeutics at The Ohio State University College of Medicine, where he holds the Ralph W. Kurtz Endowed Chair. He is the deputy director for basic research at the OSU Comprehensive Cancer Center and a founding co-director of the Center for Cancer Engineering. His research has advanced understanding of the signaling pathways that drive thyroid cancer progression and therapeutic resistance, as well as the genetic factors that predispose patients to thyroid cancer. Ringel is a former editor-in-chief of Endocrine-Related Cancer and served as co-chair of the 2025 American Thyroid Association Thyroid Cancer Guidelines.
How to Attend:
In Person:
S-214, Medical Sciences Building (513 Parnassus Avenue)
Lunch will be provided
Or join by phone (for higher quality, dial a number based on your current location):
+1 669 900 6833 US (San Jose)
+1 213 338 8477 US (Los Angeles)
+1 669 219 2599 US (San Jose)
+52 554 161 4288 (Mexico)
New procedures for claiming CME credit:
Please review this informational guide on the updated ways to claim CME credit starting in academic year 25-26.
Add to Calendar2026-05-19 19:00:002026-05-19 20:00:00Updated Thyroid Cancer Guidelines: Personalized Approaches for Optimized Care
This Grand Rounds will examine the American Thyroid Association’s 2025 guidelines and their implications for the care of patients with thyroid cancer. Matthew Ringel, an expert in endocrine-related cancers and a visiting professor from The Ohio State University College of Medicine, will discuss evolving approaches to early-stage disease, the role of molecular testing in diagnosis and treatment planning, and management strategies for radioiodine-resistant disease. The session will highlight practical considerations for applying guideline-based care across diverse clinical presentations.
Speaker:
Matthew Ringel, MD, is the founding chair of the Department of Molecular Medicine and Therapeutics at The Ohio State University College of Medicine, where he holds the Ralph W. Kurtz Endowed Chair. He is the deputy director for basic research at the OSU Comprehensive Cancer Center and a founding co-director of the Center for Cancer Engineering. His research has advanced understanding of the signaling pathways that drive thyroid cancer progression and therapeutic resistance, as well as the genetic factors that predispose patients to thyroid cancer. Ringel is a former editor-in-chief of Endocrine-Related Cancer and served as co-chair of the 2025 American Thyroid Association Thyroid Cancer Guidelines.
How to Attend:
In Person:
S-214, Medical Sciences Building (513 Parnassus Avenue)
Lunch will be provided
Zoom option:
https://ucsf.zoom.us/j/97633865272?pwd=sHvIef57IXKYFnBm2lnvQtxUMeRVEn.1
Webinar ID: 976 3386 5272
Passcode: 609641
Or join by phone (for higher quality, dial a number based on your current location):
+1 669 900 6833 US (San Jose)
+1 213 338 8477 US (Los Angeles)
+1 669 219 2599 US (San Jose)
+52 554 161 4288 (Mexico)
International numbers available: https://ucsf.zoom.us/u/ac4WisOf7E
New procedures for claiming CME credit:
Please review this informational guide on the updated ways to claim CME credit starting in academic year 25-26.
Department of MedicineAmerica/Los_Angelespublic
